相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study
Antoinette O'Connor et al.
MOLECULAR PSYCHIATRY (2021)
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Shorena Janelidze et al.
NATURE MEDICINE (2020)
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Elisabeth H. Thijssen et al.
NATURE MEDICINE (2020)
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Shorena Janelidze et al.
NATURE COMMUNICATIONS (2020)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
Thomas K. Karikari et al.
LANCET NEUROLOGY (2020)
The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics
Sarah A. Kent et al.
ACTA NEUROPATHOLOGICA (2020)
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
Juan Lantero Rodriguez et al.
ACTA NEUROPATHOLOGICA (2020)
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays
Sebastien Boulo et al.
ALZHEIMERS & DEMENTIA (2020)
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease
Nicolas R. Barthelemy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Neuropathological assessment of the Alzheimer spectrum
Kurt A. Jellinger
JOURNAL OF NEURAL TRANSMISSION (2020)
Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease
Philip S. J. Weston et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Neurofilament light chain as a biomarker in neurological disorders
Lorenzo Gaetani et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson et al.
JAMA NEUROLOGY (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
Sebastian Palmqvist et al.
JAMA NEUROLOGY (2019)
Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography
Niklas Mattsson et al.
JAMA NEUROLOGY (2019)
The neuropathological diagnosis of Alzheimer's disease
Michael A. DeTure et al.
MOLECULAR NEURODEGENERATION (2019)
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Sebastian Palmqvist et al.
EMBO MOLECULAR MEDICINE (2019)
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease
Maria Joao Leitao et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease
Oliver Preische et al.
NATURE MEDICINE (2019)
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays
Kaj Blennow et al.
SCIENTIFIC REPORTS (2019)
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Malgorzata Rozga et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography
Michelle M. Mielke et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Update on biomarkers for amyloid pathology in Alzheimer's disease
Nicholas J. Ashton et al.
BIOMARKERS IN MEDICINE (2018)
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Akinori Nakamura et al.
NATURE (2018)
Tau Kinetics in Neurons and the Human Central Nervous System (vol 97, pg 1284, 2018)
Chihiro Sato et al.
NEURON (2018)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Leslie M. Shaw et al.
ALZHEIMERS & DEMENTIA (2018)
The glymphatic pathway in neurological disorders
Martin Kaag Rasmussen et al.
LANCET NEUROLOGY (2018)
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team
Stephen P. Arneric et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Cerebrospinal Fluid A beta(42/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimer's Disease
Piotr Lewczuk et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients
Nzeera Ketter et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome
Harutsugu Tatebe et al.
MOLECULAR NEURODEGENERATION (2017)
Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease
Joana B. Pereira et al.
NEUROBIOLOGY OF AGING (2017)
Review: Tau in biofluids - relation to pathology, imaging and clinical features
H. Zetterberg
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2017)
Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
Ann De Vos et al.
BMC NEUROLOGY (2017)
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Vitaliy Ovod et al.
ALZHEIMERS & DEMENTIA (2017)
CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation
Julia Kuhlmann et al.
CLINICA CHIMICA ACTA (2017)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Tauopathies as clinicopathological entities
David J. Irwin
PARKINSONISM & RELATED DISORDERS (2016)
Dissecting Temporal Profiles of Neuronal and Axonal Damage After Mild Traumatic Brain Injury
Tanya Bogoslovsky et al.
JAMA NEUROLOGY (2016)
Plasma β-amyloid in Alzheimer's disease and vascular disease
Shorena Janelidze et al.
SCIENTIFIC REPORTS (2016)
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
Joakim Bergman et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia
Tobias Skillback et al.
BRAIN (2015)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2014)
Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease Results From the Swedish Mortality Registry
Tobias Skillback et al.
JAMA NEUROLOGY (2014)
Biomarker Modeling of Alzheimer's Disease
Clifford R. Jack et al.
NEURON (2013)
Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study
Jeffrey Randall et al.
RESUSCITATION (2013)
Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein
Luis F. Maia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
M. Öst et al.
NEUROLOGY (2006)
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease - A comparative cerebrospinal fluid study
H Hampel et al.
ARCHIVES OF GENERAL PSYCHIATRY (2004)
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D Strozyk et al.
NEUROLOGY (2003)
Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease
N Itoh et al.
ANNALS OF NEUROLOGY (2001)
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
C Hesse et al.
NEUROSCIENCE LETTERS (2001)
分享论文
